Page 34 - Celularity Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating GX Acquisition Corp. ("GXGX" or the "Company") ( ) relating to its proposed merger with Celularity, Inc. Under the terms of the agreement, GXGX will acquire Celularity through a reverse merger, with Celularity emerging as a publicly traded company. The investigation focuses on whether GX Acquisition Corp. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a...

Posted on 7440 Wren Therapeutics Ltd., (“Wren”), a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, today announced the closing of a £12.4 million (c. $17.0 million) financing. This financing brings the total capital raised to date to approximately £33 million (c. $45 million). The financing was led by existing shareholder The Baupost Group, with participation from existing investors including LifeForce Capital and new investors including Schooner Capit...

Press release content from Business Wire. The AP news staff was not involved in its creation. Wren Therapeutics Announces Financing of £12.4 Million (c. $17.0 Million) January 25, 2021 GMT CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Jan 25, 2021-- Wren Therapeutics Ltd., (“Wren”), a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, today announced the closing of a £12.4 million (c. $17.0 million) financing. This financing brings the total capital raised to date to approximately £33 million (c. $45 million). The fi...

WILMINGTON, Del., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating GX Acquisition Corp. ("GX Acquisition") (NADAQ ...

Share this article Share this article FLORHAM PARK, N.J., Jan. 20, 2021 /PRNewswire/ -- Celularity Inc., a clinical stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular therapies, today announced that Robert J. Hariri, M.D., Ph.D., Founder, Chairperson and Chief Executive Officer of Celularity and members of the management team will be participating in a fireside chat at the B. Riley Virtual Oncology Investor Conference on Thursday, January 21, 2021, at 3:30 p.m. ET The live audience is limited to institutional investors, investor rela...